Which Is the Better Passive Income Stock, Eli Lilly or Bristol Myers Squibb?
Most pharma investors are familiar with power players like Eli Lilly (NYSE: LLY) and Bristol Myers Squibb, (NYSE: BMY) and both businesses have a lot to offer passive income investors too. The pair pay out reliably, and both have a habit of hiking their payments over time alongside their growing earnings.
But don't take that to mean they're of equal merit as dividend stocks, as there's a clear winner in this match-up. Let's investigate in more detail to determine which one is the better option and why.
Image source: Getty Images.
Source Fool.com